Program
Esomeprazole
Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.
Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.
Drug pageEsomeprazole: every studyMany companies study it; this page follows only the 122 they lead. All 244 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 920 open or running | phase 4since Sep 12, 2005 | Mar 16, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Sep 4, 2019 | Dec 8, 2017 | none ahead |
| Aralez Pharmaceuticalsits history only | 40 open or running | phase 1since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 1since Feb 6, 2018 | Feb 6, 2018 | none ahead |
| Pfizerits history only | 30 open or running | phase 4since Jan 21, 2016 | Feb 25, 2012 | none ahead |
| Takedaits history only | 30 open or running | phase 2since Apr 14, 2016 | Jul 16, 2009 | none ahead |
| Torrent Pharmaceuticalsits history only | 30 open or running | phase 1since Nov 9, 2015 | Nov 9, 2015 | none ahead |
| EMSits history only | 20 open or running | phase 4since Sep 2, 2015 | Sep 2, 2015 | none ahead |
| Elpen Pharmaceuticalits history only | 10 open or running | phase 4since Nov 7, 2016 | Nov 7, 2016 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since Oct 31, 2011 | Oct 31, 2011 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Sep 6, 2021 | Sep 6, 2021 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Feb 22, 2022 | Feb 22, 2022 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Apr 20, 2007 | Apr 20, 2007 | none ahead |
| Joincare Pharmaceutical Group Industryits history only | 11 open or running | phase 3since Feb 7, 2025 | Feb 7, 2025 | none ahead |
| SD Biosensorits history only | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: IQVIA RDS, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, CISCRP, Arvinas Estrogen Receptor, Parexel and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eurofarma Laboratorios only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2011First study: phase 3 study in Gastroesophageal RefluxFirst studyNCT01471925 · Brazil
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The one study Eurofarma Laboratorios leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01471925Gastroesophageal Reflux · Brazil | 3 | Withdrawn | 0 |
How it is read
Names in the registry
- “Esomeprazole”, 72 entries
- “esomeprazole”, 8 entries
- “PN400”, 8 entries
- “Esomeprazole (Nexium)”, 3 entries
- “HIP1601”, 3 entries
Codes read as this program: D961H, D026.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 40 studies
- Stomach Ulcer, 13 studies
- Heartburn, 9 studies
- Esophagitis, Peptic, 6 studies
- Gastrointestinal Diseases, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.